{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:03:15Z","timestamp":1795100595811,"version":"4.10.3"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["KEIT 20018560"],"award-info":[{"award-number":["KEIT 20018560"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["NTIS 2410005252"],"award-info":[{"award-number":["NTIS 2410005252"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["RS-2024-00448758"],"award-info":[{"award-number":["RS-2024-00448758"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00405818"],"award-info":[{"award-number":["RS-2024-00405818"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00213691"],"award-info":[{"award-number":["RS-2023-00213691"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03109-3","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T23:44:31Z","timestamp":1739144671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Drug delivery strategies with lipid-based nanoparticles for Alzheimer\u2019s disease treatment"],"prefix":"10.1186","volume":"23","author":[{"given":"Young-Ju","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-El","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Hwa","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Kee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Ho","family":"Bhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"1","key":"3109_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"S Przedborski","year":"2003","unstructured":"Przedborski S, Vila M, Jackson-Lewis V. Series introduction: neurodegeneration: what is it and where are we? J Clin Investig. 2003;111(1):3\u201310.","journal-title":"J Clin Investig"},{"issue":"4","key":"3109_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim M-O, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4): a033118.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"3109_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","volume":"8","author":"M Calabr\u00f2","year":"2021","unstructured":"Calabr\u00f2 M, et al. The biological pathways of Alzheimer disease: a review. AIMS Neurosci. 2021;8(1):86.","journal-title":"AIMS Neurosci"},{"issue":"2","key":"3109_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","volume":"108","author":"N Iwata","year":"2005","unstructured":"Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-\u03b2 peptide and Alzheimer\u2019s disease. Pharmacol Ther. 2005;108(2):129\u201348.","journal-title":"Pharmacol Ther"},{"key":"3109_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","volume":"1","author":"DM Skovronsky","year":"2006","unstructured":"Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol. 2006;1:151\u201370.","journal-title":"Annu Rev Pathol"},{"issue":"15","key":"3109_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM. Parkinson\u2019s disease. First of two parts. N Engl J Med. 1998;339(15):1044\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"3109_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000381546","volume":"1","author":"X Chen","year":"2014","unstructured":"Chen X, Pan W. The treatment strategies for neurodegenerative diseases by integrative medicine. Integr Med Int. 2014;1(4):223\u20135.","journal-title":"Integr Med Int"},{"key":"3109_CR8","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.2147\/IJN.S87148","volume":"10","author":"B Fonseca-Santos","year":"2015","unstructured":"Fonseca-Santos B, Gremiao MP, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomed. 2015;10:4981\u20135003.","journal-title":"Int J Nanomed"},{"key":"3109_CR9","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, et al. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3109_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"LK Huang","year":"2020","unstructured":"Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.","journal-title":"J Biomed Sci"},{"issue":"4\u20135","key":"3109_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","volume":"421","author":"SL La Porte","year":"2012","unstructured":"La Porte SL, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease. J Mol Biol. 2012;421(4\u20135):525\u201336.","journal-title":"J Mol Biol"},{"issue":"4","key":"3109_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696\u2013701.","journal-title":"Alzheimers Dement"},{"key":"3109_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-8-36","volume":"8","author":"CA Lemere","year":"2013","unstructured":"Lemere CA. Immunotherapy for Alzheimer\u2019s disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.","journal-title":"Mol Neurodegener"},{"key":"3109_CR14","first-page":"9343514","volume":"2022","author":"SA Beshir","year":"2022","unstructured":"Beshir SA, et al. Aducanumab therapy to treat Alzheimer\u2019s disease: a narrative review. Int J Alzheimers Dis. 2022;2022:9343514.","journal-title":"Int J Alzheimers Dis"},{"key":"3109_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/197452a0","author":"AJ Becker","year":"1963","unstructured":"Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963. https:\/\/doi.org\/10.1038\/197452a0.","journal-title":"Nature"},{"issue":"7","key":"3109_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","volume":"64","author":"Y Chen","year":"2012","unstructured":"Chen Y, Liu L. Modern methods for delivery of drugs across the blood\u2013brain barrier. Adv Drug Deliv Rev. 2012;64(7):640\u201365.","journal-title":"Adv Drug Deliv Rev"},{"issue":"21","key":"3109_CR17","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1111\/febs.13412","volume":"282","author":"J Keaney","year":"2015","unstructured":"Keaney J, Campbell M. The dynamic blood\u2013brain barrier. FEBS J. 2015;282(21):4067\u201379.","journal-title":"FEBS J"},{"issue":"2","key":"3109_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13770-022-00503-y","volume":"20","author":"Y Sun","year":"2023","unstructured":"Sun Y, et al. Engineered extracellular vesicles as a targeted delivery platform for precision therapy. Tissue Eng Regener Med. 2023;20(2):157\u201375.","journal-title":"Tissue Eng Regener Med"},{"key":"3109_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00670-x","volume":"12","author":"M Guo","year":"2020","unstructured":"Guo M, et al. Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2020;12:1\u201314.","journal-title":"Alzheimer's Res Therapy"},{"issue":"1","key":"3109_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12951-021-00864-x","volume":"19","author":"A Cano","year":"2021","unstructured":"Cano A, et al. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer\u2019s disease: from current to future challenges. J Nanobiotechnol. 2021;19(1):122.","journal-title":"J Nanobiotechnol"},{"key":"3109_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121690","volume":"288","author":"G Zhong","year":"2022","unstructured":"Zhong G, et al. Blood-brain barrier Permeable nanoparticles for Alzheimer\u2019s disease treatment by selective mitophagy of microglia. Biomaterials. 2022;288:121690.","journal-title":"Biomaterials"},{"issue":"1","key":"3109_CR22","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):4790.","journal-title":"Nat Commun"},{"issue":"19","key":"3109_CR23","doi-asserted-by":"publisher","first-page":"1807965","DOI":"10.1002\/adma.201807965","volume":"31","author":"D Kim","year":"2019","unstructured":"Kim D, Kwon HJ, Hyeon T. Magnetite\/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-\u03b2 in Alzheimer\u2019s disease. Adv Mater. 2019;31(19):1807965.","journal-title":"Adv Mater"},{"issue":"3","key":"3109_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000381511","volume":"15","author":"K Konishi","year":"2015","unstructured":"Konishi K, et al. Hypothesis of endogenous anticholinergic activity in Alzheimer\u2019s disease. Neurodegener Dis. 2015;15(3):149\u201356.","journal-title":"Neurodegener Dis"},{"key":"3109_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"PP Liu","year":"2019","unstructured":"Liu PP, et al. History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct Target Ther. 2019;4:29.","journal-title":"Signal Transduct Target Ther"},{"key":"3109_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-981-10-8488-1_9","volume-title":"Nicotinic acetylcholine receptor signaling in neuroprotection","author":"K Fukunaga","year":"2018","unstructured":"Fukunaga K, Yabuki Y. SAK3-induced neuroprotection is mediated by nicotinic acetylcholine receptors. In: Akaike A, Shimohama S, Misu Y, editors. Nicotinic acetylcholine receptor signaling in neuroprotection. Singapore: Springer Singapore; 2018. p. 159\u201371. https:\/\/doi.org\/10.1007\/978-981-10-8488-1_9."},{"key":"3109_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.compbiolchem.2017.04.002","volume":"68","author":"SP Singh","year":"2017","unstructured":"Singh SP, Gupta D. Discovery of potential inhibitor against human acetylcholinesterase: a molecular docking and molecular dynamics investigation. Comput Biol Chem. 2017;68:224\u201330.","journal-title":"Comput Biol Chem"},{"issue":"7","key":"3109_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2174\/1871527313666140917121132","volume":"13","author":"AM Tata","year":"2014","unstructured":"Tata AM, et al. Cholinergic system dysfunction and neurodegenerative diseases: cause or effect? CNS Neurol Disord Drug Targets. 2014;13(7):1294\u2013303.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"3109_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","volume":"65","author":"NC Danbolt","year":"2001","unstructured":"Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1\u2013105.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"3109_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1523\/JNEUROSCI.07-02-00357.1987","volume":"7","author":"DW Choi","year":"1987","unstructured":"Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987;7(2):357\u201368.","journal-title":"J Neurosci"},{"issue":"4\u20135","key":"3109_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0143-4160(03)00128-3","volume":"34","author":"MP Mattson","year":"2003","unstructured":"Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer\u2019s disease. Cell Calcium. 2003;34(4\u20135):385\u201397.","journal-title":"Cell Calcium"},{"issue":"6","key":"3109_CR32","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1523\/JNEUROSCI.05-06-01483.1985","volume":"5","author":"SM Rothman","year":"1985","unstructured":"Rothman SM. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J Neurosci. 1985;5(6):1483\u20139.","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"3109_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/0006-8993(91)91140-V","volume":"548","author":"JY Koh","year":"1991","unstructured":"Koh JY, Choi DW. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res. 1991;548(1\u20132):318\u201321.","journal-title":"Brain Res"},{"issue":"2\u20133","key":"3109_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0143-4160(98)90115-4","volume":"23","author":"SA Lipton","year":"1998","unstructured":"Lipton SA, Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium. 1998;23(2\u20133):165\u201371.","journal-title":"Cell Calcium"},{"issue":"5054","key":"3109_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"issue":"5","key":"3109_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, et al. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5):a006270.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"3109_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, et al. Alzheimer\u2019s-causing mutations shift abeta length by destabilizing gamma-secretase-abetan interactions. Cell. 2017;170(3):443\u201356.","journal-title":"Cell"},{"issue":"7","key":"3109_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006338","volume":"2","author":"L Mucke","year":"2012","unstructured":"Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7):a006338.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5580","key":"3109_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"1","key":"3109_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"3109_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/NEN.0b013e318217a118","volume":"70","author":"B DaRocha-Souto","year":"2011","unstructured":"DaRocha-Souto B, et al. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein\/tau transgenic mice. J Neuropathol Exp Neurol. 2011;70(5):360\u201376.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"3109_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1046\/j.1460-9568.2003.02444.x","volume":"17","author":"D Van Dam","year":"2003","unstructured":"Van Dam D, et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17(2):388\u201396.","journal-title":"Eur J Neurosci"},{"issue":"10","key":"3109_CR43","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang J, et al. A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol. 2017;13(10):612\u201323.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"3109_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"29","key":"3109_CR45","doi-asserted-by":"publisher","first-page":"20318","DOI":"10.1074\/jbc.M114.554725","volume":"289","author":"S Kumar","year":"2014","unstructured":"Kumar S, et al. Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity. J Biol Chem. 2014;289(29):20318\u201332.","journal-title":"J Biol Chem"},{"issue":"5733","key":"3109_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2005","unstructured":"Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476\u201381.","journal-title":"Science"},{"issue":"1","key":"3109_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25(1):59\u201370.","journal-title":"Eur J Neurol"},{"key":"3109_CR48","doi-asserted-by":"crossref","unstructured":"Comfort, Cholinesterase inhibition in treatment of Alzheimer's dementia. Lancet. 1978; 1(8065): 659\u201360.","DOI":"10.1016\/S0140-6736(78)91161-3"},{"issue":"11","key":"3109_CR49","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ncpneuro0269","volume":"2","author":"PV Rabins","year":"2006","unstructured":"Rabins PV, Lyketsos CG. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer\u2019s disease. Nat Clin Pract Neurol. 2006;2(11):578\u20139.","journal-title":"Nat Clin Pract Neurol"},{"key":"3109_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: recent treatment strategies. Eur J Pharmacol. 2020;887:173554.","journal-title":"Eur J Pharmacol"},{"key":"3109_CR51","volume":"2","author":"J Birks","year":"2009","unstructured":"Birks J, et al. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2009;2:CD001191.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3109_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-014-0197-x","volume":"31","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Rivastigmine transdermal patch 13.3 mg\/24 h: a review of its use in the management of mild to moderate Alzheimer\u2019s dementia. Drugs Aging. 2014;31(8):639\u201349.","journal-title":"Drugs Aging"},{"issue":"17","key":"3109_CR53","first-page":"1642","volume":"327","author":"HD Larkin","year":"2022","unstructured":"Larkin HD. First donepezil transdermal patch approved for Alzheimer Disease. JAMA. 2022;327(17):1642.","journal-title":"JAMA"},{"issue":"2","key":"3109_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","volume":"39","author":"A Atri","year":"2019","unstructured":"Atri A. Current and future treatments in Alzheimer\u2019s disease. Semin Neurol. 2019;39(2):227\u201340.","journal-title":"Semin Neurol"},{"issue":"1","key":"3109_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/jgs.15069","volume":"66","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66(1):170\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"3109_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish PV, et al. New approaches for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett. 2019;29(2):125\u201333.","journal-title":"Bioorg Med Chem Lett"},{"key":"3109_CR57","unstructured":"Namzaric (memantine hydrochloride extended-release\/donepezil hydrochloride) capsules. 2014, US Food and Drug Administration."},{"issue":"15","key":"3109_CR58","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/14656566.2018.1519022","volume":"19","author":"A Calhoun","year":"2018","unstructured":"Calhoun A, et al. An evaluation of memantine ER + donepezil for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother. 2018;19(15):1711\u20137.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"3109_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183586","volume":"12","author":"R Chen","year":"2017","unstructured":"Chen R, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS ONE. 2017;12(8):e0183586.","journal-title":"PLoS ONE"},{"issue":"11","key":"3109_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1831","volume":"10","author":"J Guo","year":"2020","unstructured":"Guo J, et al. Memantine, donepezil, or combination therapy\u2014hat is the best therapy for Alzheimer\u2019s Disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831.","journal-title":"Brain Behav"},{"key":"3109_CR61","doi-asserted-by":"publisher","first-page":"8501693","DOI":"10.1155\/2016\/8501693","volume":"2016","author":"J Folch","year":"2016","unstructured":"Folch J, et al. Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast. 2016;2016:8501693.","journal-title":"Neural Plast"},{"issue":"15","key":"3109_CR62","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, et al. Randomized trial of verubecestat for prodromal ALZHEIMER\u2019S disease. N Engl J Med. 2019;380(15):1408\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"3109_CR63","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMc1813435","volume":"380","author":"D Henley","year":"2019","unstructured":"Henley D, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease. N Engl J Med. 2019;380(15):1483\u20135.","journal-title":"N Engl J Med"},{"key":"3109_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","volume":"5","author":"C Lopez Lopez","year":"2019","unstructured":"Lopez Lopez C, et al. The Alzheimer\u2019s prevention initiative generation program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2019;5:216\u201327.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"3109_CR65","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","volume":"18","author":"F Panza","year":"2018","unstructured":"Panza F, et al. BACE inhibitors in clinical development for the treatment of Alzheimer\u2019s disease. Expert Rev Neurother. 2018;18(11):847\u201357.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"3109_CR66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2020","unstructured":"Wessels AM, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 2020;77(2):199\u2013209.","journal-title":"JAMA Neurol"},{"issue":"12","key":"3109_CR67","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/nn1797","volume":"9","author":"X Hu","year":"2006","unstructured":"Hu X, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9(12):1520\u20135.","journal-title":"Nat Neurosci"},{"issue":"26","key":"3109_CR68","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.1523\/JNEUROSCI.1334-10.2010","volume":"30","author":"X Hu","year":"2010","unstructured":"Hu X, et al. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30(26):8819\u201329.","journal-title":"J Neurosci"},{"key":"3109_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1326-5-31","volume":"5","author":"BD Hitt","year":"2010","unstructured":"Hitt BD, et al. BACE1-\/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener. 2010;5:31.","journal-title":"Mol Neurodegener"},{"issue":"50","key":"3109_CR70","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird FM, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25(50):11693\u2013709.","journal-title":"J Neurosci"},{"issue":"5799","key":"3109_CR71","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.1132341","volume":"314","author":"M Willem","year":"2006","unstructured":"Willem M, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314(5799):664\u20136.","journal-title":"Science"},{"key":"3109_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-pharmtox-011613-135932","volume":"54","author":"K Chiang","year":"2014","unstructured":"Chiang K, Koo EH. Emerging therapeutics for Alzheimer\u2019s disease. Annu Rev Pharmacol Toxicol. 2014;54:381\u2013405.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"3109_CR73","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72(11):1324\u201333.","journal-title":"JAMA Neurol"},{"issue":"4","key":"3109_CR74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369(4):341\u201350.","journal-title":"N Engl J Med"},{"issue":"4","key":"3109_CR75","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","volume":"159","author":"B De Strooper","year":"2014","unstructured":"De Strooper B. Lessons from a failed gamma-secretase Alzheimer trial. Cell. 2014;159(4):721\u20136.","journal-title":"Cell"},{"issue":"12","key":"3109_CR76","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2174\/156802611795860942","volume":"11","author":"BP Imbimbo","year":"2011","unstructured":"Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer\u2019s disease: disappointments and hopes. Curr Top Med Chem. 2011;11(12):1555\u201370.","journal-title":"Curr Top Med Chem"},{"issue":"7738","key":"3109_CR77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0813-8","volume":"565","author":"G Yang","year":"2019","unstructured":"Yang G, et al. Structural basis of Notch recognition by human gamma-secretase. Nature. 2019;565(7738):192\u20137.","journal-title":"Nature"},{"issue":"3","key":"3109_CR78","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1172\/JCI18162","volume":"112","author":"JL Eriksen","year":"2003","unstructured":"Eriksen JL, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440\u20139.","journal-title":"J Clin Invest"},{"key":"3109_CR79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.neulet.2019.02.011","volume":"701","author":"W Xia","year":"2019","unstructured":"Xia W. gamma-Secretase and its modulators: twenty years and beyond. Neurosci Lett. 2019;701:162\u20139.","journal-title":"Neurosci Lett"},{"issue":"23","key":"3109_CR80","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557\u201364.","journal-title":"JAMA"},{"issue":"2","key":"3109_CR81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76(2):185\u2013205.","journal-title":"Ann Neurol"},{"key":"3109_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25071659","author":"B Penke","year":"2020","unstructured":"Penke B, Szucs M, Bogar F. Oligomerization and conformational change turn monomeric beta-amyloid and tau proteins toxic: their role in Alzheimer\u2019s pathogenesis. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25071659.","journal-title":"Molecules"},{"issue":"6","key":"3109_CR83","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13(6):550\u20137.","journal-title":"J Nutr Health Aging"},{"issue":"6","key":"3109_CR84","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","volume":"85","author":"D Fenili","year":"2007","unstructured":"Fenili D, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl). 2007;85(6):603\u201311.","journal-title":"J Mol Med (Berl)"},{"issue":"7","key":"3109_CR85","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nm1423","volume":"12","author":"J McLaurin","year":"2006","unstructured":"McLaurin J, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12(7):801\u20138.","journal-title":"Nat Med"},{"issue":"13","key":"3109_CR86","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"S Salloway","year":"2011","unstructured":"Salloway S, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77(13):1253\u201362.","journal-title":"Neurology"},{"issue":"2","key":"3109_CR87","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/JAD-160965","volume":"58","author":"MS Rafii","year":"2017","unstructured":"Rafii MS, et al. A randomized, double-blind, placebo-controlled, phase II study of oral ELND005 (scyllo-Inositol) in young adults with Down syndrome without dementia. J Alzheimers Dis. 2017;58(2):401\u201311.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"3109_CR88","first-page":"149","volume":"4","author":"S Abushakra","year":"2017","unstructured":"Abushakra S, et al. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4(3):149\u201356.","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"3109_CR89","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"JA Hey","year":"2018","unstructured":"Hey JA, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of ALZHEIMER\u2019S disease. Clin Pharmacokinet. 2018;57(3):315\u201333.","journal-title":"Clin Pharmacokinet"},{"issue":"6740","key":"3109_CR90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173\u20137.","journal-title":"Nature"},{"issue":"9","key":"3109_CR91","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553\u201362.","journal-title":"Neurology"},{"issue":"1","key":"3109_CR92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46\u201354.","journal-title":"Neurology"},{"issue":"7","key":"3109_CR93","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll JAR, et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer\u2019s disease. Brain. 2019;142(7):2113\u201326.","journal-title":"Brain"},{"issue":"1","key":"3109_CR94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","volume":"3","author":"R Vandenberghe","year":"2017","unstructured":"Vandenberghe R, et al. Active Abeta immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study. Alzheimers Dement (N Y). 2017;3(1):10\u201322.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"3109_CR95","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"11","author":"B Winblad","year":"2012","unstructured":"Winblad B, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11(7):597\u2013604.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3109_CR96","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1567205014666170117101537","volume":"14","author":"M Hull","year":"2017","unstructured":"Hull M, et al. Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer\u2019s disease. Curr Alzheimer Res. 2017;14(7):696\u2013708.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"3109_CR97","first-page":"192","volume":"3","author":"N Ketter","year":"2016","unstructured":"Ketter N, et al. A randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with QS-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2016;3(4):192\u2013201.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"3109_CR98","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","volume":"10","author":"AM Lacosta","year":"2018","unstructured":"Lacosta AM, et al. Safety, tolerability and immunogenicity of an active anti-Abeta(40) vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther. 2018;10(1):12.","journal-title":"Alzheimers Res Ther"},{"key":"3109_CR99","unstructured":"Molina E, et al. Update phase 2 study of Abvac40, an active vaccine anti-AB40 in patients with mild cognitive impairment or very-mild alzheimer\u2019s disease, in ADPD 2022, International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. 2022: Barcelona, Spain."},{"issue":"16","key":"3109_CR100","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","volume":"33","author":"B Liu","year":"2013","unstructured":"Liu B, et al. MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe\/PS1DeltaE9 transgenic mice. J Neurosci. 2013;33(16):7027\u201337.","journal-title":"J Neurosci"},{"issue":"23","key":"3109_CR101","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1073\/pnas.0703137104","volume":"104","author":"A Muhs","year":"2007","unstructured":"Muhs A, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A. 2007;104(23):9810\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3109_CR102","first-page":"103","volume":"2","author":"A Schneeberger","year":"2015","unstructured":"Schneeberger A, et al. Results from a Phase II study to assess the clinical and immunological activity of AFFITOPE(R) AD02 in patients with early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2015;2(2):103\u201314.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"3109_CR103","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","volume":"3","author":"CY Wang","year":"2017","unstructured":"Wang CY, et al. UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2017;3(2):262\u201372.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"18","key":"3109_CR104","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2018;378(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"4","key":"3109_CR105","first-page":"219","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, et al. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect.\u201d J Prev Alzheimers Dis. 2016;3(4):219\u201328.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"3109_CR106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, et al. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7(1):102\u201311.","journal-title":"Arch Med Sci"},{"issue":"15","key":"3109_CR107","first-page":"1460","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, et al. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med. 2014;370(15):1460.","journal-title":"N Engl J Med"},{"issue":"1","key":"3109_CR108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.","journal-title":"Alzheimers Res Ther"},{"issue":"13","key":"3109_CR109","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/1567205015666180821114813","volume":"15","author":"S Salloway","year":"2018","unstructured":"Salloway S, et al. Long-term safety and efficacy of bapineuzumab in patients with mild-to-moderate Alzheimer\u2019s disease: a phase 2 open-label extension study. Curr Alzheimer Res. 2018;15(13):1231\u201343.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"3109_CR110","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378(4):321\u201330.","journal-title":"N Engl J Med"},{"key":"3109_CR111","unstructured":"NIA, NIA statement on study results suggesting solanezumab does not reduce cognitive decline in people at risk for developing Alzheimer\u2019s. 2023, National Institute on Aging: National Institutes of Health."},{"issue":"28","key":"3109_CR112","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci. 2012;32(28):9677\u201389.","journal-title":"J Neurosci"},{"issue":"21","key":"3109_CR113","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889\u201397.","journal-title":"Neurology"},{"key":"3109_CR114","unstructured":"Roche, Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD)\u2010other company programmes in AD continue 2019."},{"issue":"1","key":"3109_CR115","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49\u201369.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3109_CR116","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"3109_CR117","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","volume":"14","author":"RJ Bateman","year":"2022","unstructured":"Bateman RJ, et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):178.","journal-title":"Alzheimers Res Ther"},{"issue":"7618","key":"3109_CR118","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"7","key":"3109_CR119","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol. 2019;15(7):365\u20136.","journal-title":"Nat Rev Neurol"},{"key":"3109_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/alz.047259","volume":"16","author":"S Budd Haeberlein","year":"2020","unstructured":"Budd Haeberlein S, et al. Emerge and engage topline results: phase 3 studies of aducanumab in early Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2020;16: e047259.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"10","key":"3109_CR121","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/jamainternmed.2021.4622","volume":"181","author":"R Steinbrook","year":"2021","unstructured":"Steinbrook R. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern Med. 2021;181(10):1281.","journal-title":"JAMA Intern Med"},{"issue":"S10","key":"3109_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/alz.069428","volume":"18","author":"J Murphy","year":"2022","unstructured":"Murphy J, et al. ENVISION: A phase 3b\/4 randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab in participants with early Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2022;18(S10): e069428.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"3109_CR123","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, et al. Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8(1):14.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"3109_CR124","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"3109_CR125","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"3109_CR126","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, et al. Donanemab (LY3002813) phase 1b study in alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414\u201324.","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"3109_CR127","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"6","key":"3109_CR128","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"7","key":"3109_CR129","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","volume":"13","author":"HO Tayeb","year":"2013","unstructured":"Tayeb HO, et al. Bapineuzumab and solanezumab for Alzheimer\u2019s disease: is the \u201camyloid cascade hypothesis\u201d still alive? Expert Opin Biol Ther. 2013;13(7):1075\u201384.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"3109_CR130","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"issue":"338","key":"3109_CR131","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8(338):338\u201366.","journal-title":"Sci Transl Med"},{"issue":"10062","key":"3109_CR132","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873\u201384.","journal-title":"Lancet"},{"issue":"12","key":"3109_CR133","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nrd.2017.155","volume":"16","author":"C Li","year":"2017","unstructured":"Li C, Gotz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov. 2017;16(12):863\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"3109_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104707","volume":"134","author":"A Bittar","year":"2020","unstructured":"Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134: 104707.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"3109_CR135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14283\/jpad.2018.45","volume":"6","author":"P Novak","year":"2019","unstructured":"Novak P, et al. AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis. 2019;6(1):63\u20139.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"3109_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","volume":"16","author":"P Ballabh","year":"2004","unstructured":"Ballabh P, Braun A, Nedergaard M. The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1\u201313.","journal-title":"Neurobiol Dis"},{"issue":"31","key":"3109_CR137","doi-asserted-by":"publisher","first-page":"15214","DOI":"10.1016\/S0021-9258(18)48160-4","volume":"262","author":"AK Kumagai","year":"1987","unstructured":"Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem. 1987;262(31):15214\u20139.","journal-title":"J Biol Chem"},{"issue":"4","key":"3109_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1695","volume":"13","author":"X Zhou","year":"2021","unstructured":"Zhou X, Smith QR, Liu X. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(4): e1695.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"3","key":"3109_CR139","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0169-409X(01)00141-7","volume":"49","author":"JE Schnitzer","year":"2001","unstructured":"Schnitzer JE. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Deliv Rev. 2001;49(3):265\u201380.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"3109_CR140","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.lfs.2005.06.004","volume":"78","author":"DD Allen","year":"2006","unstructured":"Allen DD, Geldenhuys WJ. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci. 2006;78(10):1029\u201333.","journal-title":"Life Sci"},{"issue":"1","key":"3109_CR141","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1602\/neurorx.2.1.54","volume":"2","author":"A Tsuji","year":"2005","unstructured":"Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx. 2005;2(1):54\u201362.","journal-title":"NeuroRx"},{"key":"3109_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123108","author":"R Abdul Razzak","year":"2019","unstructured":"Abdul Razzak R, Florence GJ, Gunn-Moore FJ. Approaches to CNS drug delivery with a focus on transporter-mediated transcytosis. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20123108.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3109_CR143","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.pneurobio.2008.12.002","volume":"87","author":"I Brasnjevic","year":"2009","unstructured":"Brasnjevic I, et al. Delivery of peptide and protein drugs over the blood\u2013brain barrier. Prog Neurobiol. 2009;87(4):212\u201351.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"3109_CR144","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chembiol.2006.11.015","volume":"14","author":"S Hong","year":"2007","unstructured":"Hong S, et al. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007;14(1):107\u201315.","journal-title":"Chem Biol"},{"key":"3109_CR145","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.colsurfb.2016.01.041","volume":"141","author":"L Li","year":"2016","unstructured":"Li L, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260\u20137.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3109_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224: 119491.","journal-title":"Biomaterials"},{"issue":"2","key":"3109_CR147","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1210\/endo-121-2-459","volume":"121","author":"P Grasso","year":"1987","unstructured":"Grasso P, et al. Transglutaminase activity in bovine calf testicular membranes: evidence for a possible role in the interaction of follicle-stimulating hormone with its receptor. Endocrinology. 1987;121(2):459\u201365.","journal-title":"Endocrinology"},{"issue":"5","key":"3109_CR148","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, et al. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat Rev Drug Discov. 2021;20(5):362\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3109_CR149","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, et al. Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982\u20137015.","journal-title":"ACS Nano"},{"key":"3109_CR150","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","volume":"6","author":"P Ganesan","year":"2017","unstructured":"Ganesan P, Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37\u201356.","journal-title":"Sustain Chem Pharm"},{"issue":"6","key":"3109_CR151","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s13770-023-00555-8","volume":"20","author":"SW Choi","year":"2023","unstructured":"Choi SW, et al. Therapeutic extracellular vesicles from tonsil-derived mesenchymal stem cells for the treatment of retinal degenerative disease. Tissue Eng Regener Med. 2023;20(6):951\u201364.","journal-title":"Tissue Eng Regener Med"},{"key":"3109_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1228679","author":"L Hu","year":"2023","unstructured":"Hu L, et al. Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. 2023. https:\/\/doi.org\/10.3389\/fcell.2023.1228679.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"3109_CR153","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrd3978","volume":"12","author":"S El Andaloussi","year":"2013","unstructured":"El Andaloussi S, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347\u201357.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"3109_CR154","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1039\/C7LC00592J","volume":"17","author":"JC Contreras-Naranjo","year":"2017","unstructured":"Contreras-Naranjo JC, Wu H-J, Ugaz VM. Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip. 2017;17(21):3558\u201377.","journal-title":"Lab Chip"},{"issue":"1","key":"3109_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-9-9","volume":"9","author":"C L\u00e4sser","year":"2011","unstructured":"L\u00e4sser C, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. 2011;9(1):1\u20138.","journal-title":"J Transl Med"},{"issue":"Suppl 3","key":"3109_CR156","volume":"8","author":"F Magni","year":"2010","unstructured":"Magni F, et al. Biomarkers discovery by peptide and protein profiling in biological fluids based on functionalized magnetic beads purification and mass spectrometry. Blood Transfus. 2010;8(Suppl 3): s92.","journal-title":"Blood Transfus"},{"key":"3109_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110413","volume":"99","author":"RSA Sattar","year":"2022","unstructured":"Sattar RSA, et al. Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery. Cell Signal. 2022;99: 110413.","journal-title":"Cell Signal"},{"key":"3109_CR158","doi-asserted-by":"crossref","unstructured":"Mu N et al. Plant-derived exosome-like nanovesicles: current progress and prospects. Int J Nanomed. 2023;18: 4987\u20135009.","DOI":"10.2147\/IJN.S420748"},{"issue":"10","key":"3109_CR159","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1002\/ange.201913700","volume":"132","author":"G Wu","year":"2020","unstructured":"Wu G, et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew Chem. 2020;132(10):4097\u2013103.","journal-title":"Angew Chem"},{"issue":"1","key":"3109_CR160","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","volume":"31","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, et al. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023;31(1):145\u201369.","journal-title":"Inflammopharmacology"},{"issue":"3","key":"3109_CR161","doi-asserted-by":"publisher","first-page":"789","DOI":"10.7150\/thno.18133","volume":"7","author":"P Li","year":"2017","unstructured":"Li P, et al. Progress in exosome isolation techniques. Theranostics. 2017;7(3):789.","journal-title":"Theranostics"},{"issue":"1","key":"3109_CR162","doi-asserted-by":"publisher","first-page":"27031","DOI":"10.3402\/jev.v4.27031","volume":"4","author":"RJ Lobb","year":"2015","unstructured":"Lobb RJ, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. 2015;4(1):27031.","journal-title":"J Extracell Vesicles"},{"key":"3109_CR163","doi-asserted-by":"crossref","unstructured":"Greening DW et al. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. Proteom profiling: Methods Protoc. 2015;1295:179\u2013209.","DOI":"10.1007\/978-1-4939-2550-6_15"},{"key":"3109_CR164","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.chroma.2014.10.026","volume":"1371","author":"ML Heinemann","year":"2014","unstructured":"Heinemann ML, et al. Benchtop isolation and characterization of functional exosomes by sequential filtration. J Chromatogr A. 2014;1371:125\u201335.","journal-title":"J Chromatogr A"},{"issue":"12","key":"3109_CR165","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.1007\/s12035-022-03044-6","volume":"59","author":"C-G Hong","year":"2022","unstructured":"Hong C-G, et al. Transplantation of nasal olfactory mucosa mesenchymal stem cells benefits Alzheimer\u2019s disease. Mol Neurobiol. 2022;59(12):7323\u201336.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"3109_CR166","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","volume":"13","author":"E Ghasempour","year":"2022","unstructured":"Ghasempour E, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. Stem Cell Res Ther. 2022;13(1):527.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"3109_CR167","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41419-020-2490-4","volume":"11","author":"H Wei","year":"2020","unstructured":"Wei H, et al. Mesenchymal stem cell-derived exosomal miR-223 regulates neuronal cell apoptosis. Cell Death Dis. 2020;11(4):290.","journal-title":"Cell Death Dis"},{"key":"3109_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116836","volume":"176","author":"N Ebrahim","year":"2024","unstructured":"Ebrahim N, et al. Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer\u2019s disease: Autophagy, insulin and the PI3K\/Akt\/mTOR signaling pathway. Biomed Pharmacother. 2024;176: 116836.","journal-title":"Biomed Pharmacother"},{"key":"3109_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-019-0150-2","volume":"16","author":"G-H Cui","year":"2019","unstructured":"Cui G-H, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer\u2019s disease. Immun Ageing. 2019;16:1\u201312.","journal-title":"Immun Ageing"},{"issue":"5","key":"3109_CR170","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/mt.2009.41","volume":"17","author":"Y Seow","year":"2009","unstructured":"Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 2009;17(5):767\u201377.","journal-title":"Mol Ther"},{"issue":"4","key":"3109_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341\u20135.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3109_CR172","doi-asserted-by":"publisher","first-page":"15731","DOI":"10.1038\/s41598-023-42485-4","volume":"13","author":"MI Khan","year":"2023","unstructured":"Khan MI, et al. Stem cells-derived exosomes alleviate neurodegeneration and Alzheimer\u2019s pathogenesis by ameliorating neuroinflamation, and regulating the associated molecular pathways. Sci Rep. 2023;13(1):15731.","journal-title":"Sci Rep"},{"issue":"6","key":"3109_CR173","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1021\/j100252a031","volume":"89","author":"P Schurtenberger","year":"1985","unstructured":"Schurtenberger P, Mazer N, K\u00e4nzig W. Micelle to vesicle transition in aqueous solutions of bile salt and lecithin. J Phys Chem. 1985;89(6):1042\u20139.","journal-title":"J Phys Chem"},{"key":"3109_CR174","doi-asserted-by":"crossref","unstructured":"Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Liposomes: methods and protocols, 2017;1522: 17\u201322.","DOI":"10.1007\/978-1-4939-6591-5_2"},{"issue":"22","key":"3109_CR175","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1016\/j.biomaterials.2013.03.097","volume":"34","author":"J-Q Gao","year":"2013","unstructured":"Gao J-Q, et al. Glioma targeting and blood\u2013brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013;34(22):5628\u201339.","journal-title":"Biomaterials"},{"issue":"1","key":"3109_CR176","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41420-021-00639-1","volume":"7","author":"X Yang","year":"2021","unstructured":"Yang X, et al. Transferrin-Pep63-liposomes accelerate the clearance of A\u03b2 and rescue impaired synaptic plasticity in early Alzheimer\u2019s disease models. Cell Death Discov. 2021;7(1):256.","journal-title":"Cell Death Discov"},{"issue":"2","key":"3109_CR177","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejps.2010.03.007","volume":"40","author":"H Chen","year":"2010","unstructured":"Chen H, et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci. 2010;40(2):94\u2013102.","journal-title":"Eur J Pharm Sci"},{"key":"3109_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodhyd.2022.107871","volume":"132","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Chitosan-coated nanoliposomes for efficient delivery of betanin with enhanced stability and bioavailability. Food Hydrocolloids. 2022;132: 107871.","journal-title":"Food Hydrocolloids"},{"key":"3109_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113270","volume":"225","author":"S Andrade","year":"2023","unstructured":"Andrade S, Pereira MC, Loureiro JA. Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer\u2019s disease therapy. Colloids Surf, B. 2023;225: 113270.","journal-title":"Colloids Surf, B"},{"key":"3109_CR180","doi-asserted-by":"crossref","unstructured":"Kong L, et al. Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice. Int J Nanomed. 2020;15: 2841\u201358.","DOI":"10.2147\/IJN.S239608"},{"issue":"22","key":"3109_CR181","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1016\/j.biomaterials.2014.03.082","volume":"35","author":"Y-C Kuo","year":"2014","unstructured":"Kuo Y-C, Wang C-T. Protection of SK-N-MC cells against \u03b2-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. Biomaterials. 2014;35(22):5954\u201364.","journal-title":"Biomaterials"},{"key":"3109_CR182","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202311670","author":"S Senapati","year":"2024","unstructured":"Senapati S, et al. Multifunctional liposomes targeting amyloid-\u03b2 oligomers for early diagnosis and therapy of Alzheimer\u2019s disease. Small. 2024. https:\/\/doi.org\/10.1002\/smll.202311670.","journal-title":"Small"},{"issue":"1","key":"3109_CR183","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1080\/10717544.2022.2072543","volume":"29","author":"J Wang","year":"2022","unstructured":"Wang J, et al. Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer\u2019s disease. Drug Delivery. 2022;29(1):1648\u201362.","journal-title":"Drug Delivery"},{"key":"3109_CR184","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jconrel.2023.12.003","volume":"365","author":"D Su","year":"2024","unstructured":"Su D, et al. MicroRNA-195 liposomes for therapy of Alzheimer\u2019s disease. J Control Release. 2024;365:583\u2013601.","journal-title":"J Control Release"},{"issue":"2","key":"3109_CR185","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1021\/acs.molpharmaceut.0c00461","volume":"18","author":"S Arora","year":"2020","unstructured":"Arora S, Layek B, Singh J. Design and validation of liposomal ApoE2 gene delivery system to evade blood\u2013brain barrier for effective treatment of Alzheimer\u2019s disease. Mol Pharm. 2020;18(2):714\u201325.","journal-title":"Mol Pharm"},{"issue":"22","key":"3109_CR186","doi-asserted-by":"publisher","first-page":"2303266","DOI":"10.1002\/adma.202303266","volume":"36","author":"M Hu","year":"2024","unstructured":"Hu M, et al. Physiological barriers and strategies of lipid-based nanoparticles for nucleic acid drug delivery. Adv Mater. 2024;36(22):2303266.","journal-title":"Adv Mater"},{"issue":"3","key":"3109_CR187","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"N Naseri","year":"2015","unstructured":"Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305.","journal-title":"Adv Pharm Bull"},{"key":"3109_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102176","volume":"61","author":"B Wilson","year":"2021","unstructured":"Wilson B, et al. Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer\u2019s disease. J Drug Deliv Sci Technol. 2021;61: 102176.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3109_CR189","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","volume":"134","author":"O Gartziandia","year":"2015","unstructured":"Gartziandia O, et al. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf, B. 2015;134:304\u201313.","journal-title":"Colloids Surf, B"},{"key":"3109_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111838","volume":"205","author":"S Saini","year":"2021","unstructured":"Saini S, et al. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: a preclinical evidence. Colloids Surf, B. 2021;205: 111838.","journal-title":"Colloids Surf, B"},{"key":"3109_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109871","volume":"249","author":"EO Mart\u00ednez","year":"2024","unstructured":"Mart\u00ednez EO, et al. Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS. Neuropharmacology. 2024;249: 109871.","journal-title":"Neuropharmacology"},{"key":"3109_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2019.107082","volume":"166","author":"T Dara","year":"2019","unstructured":"Dara T, et al. Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166: 107082.","journal-title":"Neurobiol Learn Mem"},{"key":"3109_CR193","doi-asserted-by":"crossref","unstructured":"Shehata MK, Ismail AA, Kamel MA. Combined Donepezil with Astaxanthin via nanostructured lipid carriers effective delivery to brain for Alzheimer\u2019s disease in rat model. Int J Nanomed. 2023;18: 4193\u2013227.","DOI":"10.2147\/IJN.S417928"},{"key":"3109_CR194","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2021.05.003","volume":"199","author":"E Gomaa","year":"2022","unstructured":"Gomaa E, et al. Methods for preparation of nanostructured lipid carriers. Methods. 2022;199:3\u20138.","journal-title":"Methods"},{"key":"3109_CR195","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jddst.2019.02.017","volume":"51","author":"VR Salvi","year":"2019","unstructured":"Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;51:255\u201367.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3109_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119990","volume":"285","author":"M Raju","year":"2021","unstructured":"Raju M, et al. Berberine loaded nanostructured lipid carrier for Alzheimer\u2019s disease: design, statistical optimization and enhanced in vivo performance. Life Sci. 2021;285: 119990.","journal-title":"Life Sci"},{"issue":"1","key":"3109_CR197","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10717544.2020.1745328","volume":"27","author":"Y Han","year":"2020","unstructured":"Han Y, et al. Neuronal mitochondria-targeted therapy for Alzheimer\u2019s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. Drug Delivery. 2020;27(1):502\u201318.","journal-title":"Drug Delivery"},{"issue":"1","key":"3109_CR198","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1038\/s41467-024-48461-4","volume":"15","author":"X Bian","year":"2024","unstructured":"Bian X, et al. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles. Nat Commun. 2024;15(1):3987.","journal-title":"Nat Commun"},{"issue":"15","key":"3109_CR199","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1039\/C9NR01255A","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, et al. Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT\/GSK-3\u03b2 pathway. Nanoscale. 2019;11(15):7481\u201396.","journal-title":"Nanoscale"},{"issue":"6","key":"3109_CR200","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1021\/acs.nanolett.8b04148","volume":"19","author":"N Perets","year":"2019","unstructured":"Perets N, et al. Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders. Nano Lett. 2019;19(6):3422\u201331.","journal-title":"Nano Lett"},{"issue":"2","key":"3109_CR201","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2019.11.017","volume":"28","author":"X Ge","year":"2020","unstructured":"Ge X, et al. Increased microglial exosomal miR-124-3p alleviates neurodegeneration and improves cognitive outcome after rmTBI. Mol Ther. 2020;28(2):503\u201322.","journal-title":"Mol Ther"},{"key":"3109_CR202","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2021.06.018","volume":"336","author":"M Fernandes","year":"2021","unstructured":"Fernandes M, et al. Novel concept of exosome-like liposomes for the treatment of Alzheimer\u2019s disease. J Control Release. 2021;336:130\u201343.","journal-title":"J Control Release"},{"key":"3109_CR203","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jconrel.2024.01.019","volume":"366","author":"Z Gu","year":"2024","unstructured":"Gu Z, et al. PEGylated-liposomal astaxanthin ameliorates A\u03b2 neurotoxicity and Alzheimer-related phenotypes by scavenging formaldehyde. J Control Release. 2024;366:783\u201397.","journal-title":"J Control Release"},{"key":"3109_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102434","volume":"63","author":"D Shalabalija","year":"2021","unstructured":"Shalabalija D, et al. Formulation and optimization of bioinspired rosemary extract loaded PEGylated nanoliposomes for potential treatment of Alzheimer\u2019s disease using design of experiments. J Drug Deliv Sci Technol. 2021;63: 102434.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"18","key":"3109_CR205","doi-asserted-by":"publisher","first-page":"2000515","DOI":"10.1002\/advs.202000515","volume":"7","author":"Q Lv","year":"2020","unstructured":"Lv Q, et al. Thermosensitive exosome-liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer. Adv Sci. 2020;7(18):2000515.","journal-title":"Adv Sci"},{"key":"3109_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120761","volume":"271","author":"L Sun","year":"2021","unstructured":"Sun L, et al. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials. 2021;271: 120761.","journal-title":"Biomaterials"},{"issue":"1","key":"3109_CR207","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20(1):50.","journal-title":"J Nanobiotechnol"},{"key":"3109_CR208","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.actbio.2019.05.054","volume":"94","author":"S Rayamajhi","year":"2019","unstructured":"Rayamajhi S, et al. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019;94:482\u201394.","journal-title":"Acta Biomater"},{"issue":"32","key":"3109_CR209","doi-asserted-by":"publisher","first-page":"21091","DOI":"10.1021\/acsnano.4c02560","volume":"18","author":"P Xiao","year":"2024","unstructured":"Xiao P, et al. Milk exosome-liposome hybrid vesicles with self-adapting surface properties overcome the sequential absorption barriers for oral delivery of peptides. ACS Nano. 2024;18(32):21091\u2013111.","journal-title":"ACS Nano"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03109-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03109-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03109-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:35:30Z","timestamp":1739187330000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03109-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":209,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03109-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}